CEWS

Unifor condemns FTG Aerospace's use of scab labour

Retrieved on: 
Wednesday, December 20, 2023
FTG, Government, CEWS, Social justice, Private sector, Face, Safety, Female, Renewable energy

TORONTO, Dec. 20, 2023 /CNW/ - Unifor is denouncing FTG Aerospace for using scab labour amid an ongoing labour dispute at its Toronto facility.

Key Points: 
  • TORONTO, Dec. 20, 2023 /CNW/ - Unifor is denouncing FTG Aerospace for using scab labour amid an ongoing labour dispute at its Toronto facility.
  • Approximately 70 Unifor Local 303 members have been on strike since December 11, 2023 for a fair contract.
  • Unifor is calling on FTG Aerospace management to accept the union's request to resume negotiations to end the dispute as well as immediately halt the use of scab labour at the facility.
  • It's not only a slap in the face to our FTG members, it's downright dangerous," said Brian Vance, Unifor Local 303 President.

Stingray Reports Fourth Quarter and Full Year Results for Fiscal 2023

Retrieved on: 
Tuesday, June 6, 2023
Comcast, Advertising, Partnership, Prevention of the Avoidance of Income Tax Act, ISAN, FAST, CEWS, Policy, COVID-19, Sleep, Stingray, InStore Audio Network, Cox, Interest, Comparison of multi-paradigm programming languages, Net income, Parity, EBITDA, Corporation, Acquisition, Income Tax Act, Growth, Entrepreneurship, Verizon Communications, CARIAD, Meditation, Contour, Contemporary commercial music, Xfinity Flex, News, Harman, SVOD, Video game, Security (finance), Music, Reinsurance, Holding company, Audi, Adjustment, Radio

MONTREAL, June 06, 2023 (GLOBE NEWSWIRE) -- Stingray Group Inc. (TSX: RAY.A; RAY.B) (the “Corporation”; “Stingray”), a leading distributor of audio and video music brands in the world, today announced its financial results for the fourth quarter and fiscal year ended March 31, 2023.

Key Points: 
  • Revenues in the fourth quarter increased $6.3 million, or 8.7%, to $78.9 million from $72.6 million in the fourth quarter of 2022.
  • Broadcasting and Commercial Music revenues in the fourth quarter of 2023 increased $4.4 million, or 9.8%, to $50.0 million from $45.6 million in the fourth quarter of 2022.
  • Adjusted EBITDA in the fourth quarter of 2023 increased $5.6 million, or 26.4%, to $26.6 million from $21.0 million in the fourth quarter of 2022.
  • Cash flow generated from operating activities amounted to $27.6 million in the fourth quarter of 2023 compared to $22.1 million in the fourth quarter of 2022.

Crescita Reports Q4 and Fiscal 2022 Results

Retrieved on: 
Wednesday, March 15, 2023
Cosmetics, Retail, Pharmaceutical, Health, International, Depreciation, CEWS, Commercial, Probability, Travel, Debenture, Nature, Adjustment, Investment, EBITDA, Advertising, Manufacturing Advisory Service, Growth, International Financial Reporting Standards, Pharmaceutical industry, Film industry, Cryptocurrency, Life insurance, Bookkeeping, Zein E. Obagi

For the quarter ended December 31, 2022, total revenue was $6,030 compared to $7,562 for the comparable period of F2021, representing a decrease of $1,532.

Key Points: 
  • For the quarter ended December 31, 2022, total revenue was $6,030 compared to $7,562 for the comparable period of F2021, representing a decrease of $1,532.
  • For the year ended December 31, 2022, total revenue was $23,525, compared to $16,769 for the year ended December 31, 2021, representing an increase of $6,756.
  • For the quarter ended December 31, 2022, gross profit was $3,885, representing a gross margin of 64.4%, compared to $4,651 and 61.5%, respectively, for the quarter ended December 31, 2021.
  • Cash and cash equivalents were $8,238 at December 31 2022, reflecting a net decrease of $3,093, compared to 11,331 at December 31, 2021.

Extendicare Announces 2022 Fourth Quarter and Year End Results

Retrieved on: 
Thursday, March 2, 2023
EBITDA, Saskatchewan Health Authority, Revera, Indian stock exchange, CEWS, Government, Extendicare, COVID, Long-term care, SGP, TSX, Bed, Sale, ADV, COVID-19, Growth, Partnership, LTC, NOI, Greater Toronto Area, Pharmaceutical industry, Life insurance, Axium

MARKHAM, Ontario, March 02, 2023 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three and twelve months ended December 31, 2022.

Key Points: 
  • MARKHAM, Ontario, March 02, 2023 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three and twelve months ended December 31, 2022.
  • Average long-term care (“LTC”) occupancy improved by 100 bps to 94.5%(1) from Q3 2022 despite persistent COVID-19 outbreaks, which drove elevated costs.
  • Home health care average daily volumes (“ADV”) up 2.0% from Q3 2022; 90 bps improvement in NOI margins from Q3 2022 excluding net COVID costs.
  • Governments continue to provide support for elevated pandemic costs, although the extent and timing of funding lagged, putting pressure on our financial results in the quarter.

Supremex Announces Solid Q4 2022 Results and Raises Quarterly Dividend by 16.7%

Retrieved on: 
Thursday, February 23, 2023
EBITDA, CERS, Remuneration, Conference call, Corporation, Packaging and labeling, Public expenditure, Town, Envelope, Eastern Time Zone, Absorption, Acquisition, Legislation, Conference, Leyland Royal Tiger PSU, Wind, Income Tax Act, Sale, Prevention of the Avoidance of Income Tax Act, Social Democrats (Slovenia), CEWS, Adjustment, Cryptocurrency, Video game, Retail, Webcast

Packaging & specialty products represented 22.9% of the Company’s revenue in the quarter, compared to 29.5% during the equivalent period of last year.

Key Points: 
  • Packaging & specialty products represented 22.9% of the Company’s revenue in the quarter, compared to 29.5% during the equivalent period of last year.
  • This dividend is designated as an “eligible” dividend for the purpose of the Income Tax Act (Canada) and any similar provincial legislation.
  • Driven by solid demand for its products and a robust backlog, Supremex is operating at high-capacity levels given its current labour force.
  • In terms of capital deployment for 2023, the Company expects to invest in capital expenditures and continue paying quarterly dividends.

NanoXplore Reports Strong Second Quarter Results and Increases Revenue Outlook

Retrieved on: 
Tuesday, February 14, 2023
Bank statement, Analysis, CEWS, FX, SG, Accounting, Acquisition, EBITDA, HeadCount, Surveillance of Partially Observable Systems, EST, COVID-19, Corporation, Federation, MD, Cryptocurrency

Other income decreased from $1,364,008 in the last year period to $393,111 in the current period.

Key Points: 
  • Other income decreased from $1,364,008 in the last year period to $393,111 in the current period.
  • The financial statements and MD&A were prepared using results and financial information determined under IFRS.
  • NanoXplore will hold a webcast tomorrow, February 15, 2023, at 8:30 am EST to review its second quarter results ended December 31, 2022.
  • Soroush Nazarpour, CEO and President of NanoXplore, and Pedro Azevedo, Chief Financial Officer, will host the event.

SQI Diagnostics Reports Fourth Quarter and Fiscal 2022 Results

Retrieved on: 
Tuesday, January 31, 2023
Engineering, CEWS, SQI, Corporation, Certification, PCR, COVID-19, Medical device, QMS, Quality, Research, Medicine, R, Acquisition, MDSAP, Quality management system, Science, Pharmaceutical industry, Cryptocurrency, Retail

TORONTO, Jan. 30, 2023 /PRNewswire/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2022.

Key Points: 
  • TORONTO, Jan. 30, 2023 /PRNewswire/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2022.
  • "Last fiscal year we witnessed the transition of SQI from an R&D organization to a commercial company.
  • We earned record revenues of $8.1 million in fiscal 2022 up significantly from $0.9 million in fiscal 2021.
  • The increase in sales is attributed to the COVID-19 human testing business acquired during the second quarter of fiscal 2022.

Velan Inc. Reports Solid Third Quarter 2022/23 Financial Results, With an Improving Trend in Backlog, Revenues and Profit

Retrieved on: 
Wednesday, January 11, 2023
Administration, Absorption, Movement, EBITDA, Translation, EST, CEWS, COVID-19, Drug, Film, Video game, Fossil fuel, Pharmaceutical industry

Bookings2 for the quarter amounted to $99.2 million, an increase of $10.7 million or 12.1% compared to the third quarter of last year.

Key Points: 
  • Bookings2 for the quarter amounted to $99.2 million, an increase of $10.7 million or 12.1% compared to the third quarter of last year.
  • The decrease for the nine-month period was partially offset by a strong bookings2 quarter from the Company’s North American operations which recorded significant marine orders.
  • Sales amounted to $95.2 million for the quarter, decreasing by $14.7 million or 13.4% compared to the same quarter last year.
  • Gross profit for the quarter amounted to $29.0 million, a decrease of $6.9 million or 19.2% compared to the same quarter last year.

Statement by the Minister of National Revenue, the Honourable Diane Lebouthillier and Minister and of Employment, Workforce Development and Disability Inclusion, the Honourable Carla Qualtrough on the Auditor General of Canada (OAG)'s performance audit of

Retrieved on: 
Tuesday, December 6, 2022
Canada Revenue Agency, Minister of Employment, Workforce Development and Disability Inclusion, ESDC, Federal aid during the COVID-19 pandemic in Canada, Poverty, Fraud, Social Development Canada, CRA, Employment, OAG, Employment and Social Development Canada, CERB, Government, CRB, COVID-19, Office of the Auditor General (Nepal), Parliament, CEWS, Table, Government revenue, Audit, Animal, Health insurance

This support allowed the economy to rebound and return to its pre-pandemic levels."

Key Points: 
  • This support allowed the economy to rebound and return to its pre-pandemic levels."
  • We could not agree more with the Auditor General in this regard.
  • These programs protected Canadian workers, businesses, and the economy, from the worst impacts of the pandemic.
  • Through this work, for example, CRA's audit results to date show that the vast majority of applicants met the requirements of the CEWS program.

Glacier Reports Third Quarter 2022 Results

Retrieved on: 
Monday, November 14, 2022
Joint Ventures, COVID-19, Growth, EBITDA, CRA, International Financial Reporting Standards, ERIS, Weather, Advertising, Face, Associate, Government, Environment, International, News, Exhibition, Tax, Mining, Sale, The Colony (American season 2), REW, Risk, Failure, Intelligence, Depreciation, Publication, CEWS, Investment, STP, GFM, Bank, Risk management, Air cargo

Consolidated revenue for the period ended September 30, 2022, was $47.9 million, up $7.7 million or 19.2% from the same period in the prior year.

Key Points: 
  • Consolidated revenue for the period ended September 30, 2022, was $47.9 million, up $7.7 million or 19.2% from the same period in the prior year.
  • Consolidated EBITDA for the quarter was $1.8 million, down $1.4 million from $3.2 million for the prior year.
  • These results include wage subsidies, regular and special Aid to Publishers (ATP) at varying levels and other grants and subsidies in both years.
  • Operational profits were partially offset in the quarter by continued operating investments being made in key strategic development areas.